Trials / Completed
CompletedNCT05547074
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
Development and Validation of a New Prognostic Score Model Combining TNM Stage With Immune Risk Factors for Postoperative Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 302 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | pancreatic cancer surgery | Surgical resection of pancreatic cancer，including radical or palliative surgery |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2020-10-30
- Completion
- 2022-08-31
- First posted
- 2022-09-21
- Last updated
- 2022-09-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05547074. Inclusion in this directory is not an endorsement.